Clinical Trials
33 trialsViral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV
Stanford University
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
City of Hope Medical Center
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
M.D. Anderson Cancer Center
Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection
M.D. Anderson Cancer Center
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study
National Taiwan University Hospital
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
Stanford University
A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection
Memorial Sloan Kettering Cancer Center
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
Columbia University
TRACE
University Hospital Freiburg
Gamma Capture
University of Pittsburgh
ACES
Pediatric Transplantation & Cellular Therapy Consortium
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
R-MVST Cells for Treatment of Viral Infections
Columbia University
Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
Astellas Pharma Inc
Prevent
AlloVir
Prevent
AlloVir
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT
Peking University People's Hospital
CReSCT
Melbourne Health
A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Roswell Park Cancer Institute
CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.
University Hospital, Ghent
ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
University of Minnesota
A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3
National Institute of Allergy and Infectious Diseases (NIAID)
ACE
Medical College of Wisconsin
CHARMS
AlloVir
Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection
Karolinska Institutet
i2-D²EFT
Kirby Institute
Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections
Shenzhen Geno-Immune Medical Institute
CMV_TCR-001
University College, London
Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
City of Hope Medical Center
VIRAGE
Baylor College of Medicine
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
National Cancer Institute (NCI)
Cytomegalovirus Vaccine in Healthy Participants
City of Hope Medical Center